# Predictive Factors for the Efficacy of CD19 CAR-T Therapy in Relapsed/Refractory Large B-Cell Lymphoma: A Clinical Study

> **NCT07236203** · — · RECRUITING · sponsor: **Fudan University** · enrollment: 80 (estimated)

## Conditions studied

- Large B-Cell Lymphoma

## Interventions

- **DRUG:** CAR-T

## Key facts

- **NCT ID:** NCT07236203
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2024-02-29
- **Primary completion:** 2026-08-30
- **Final completion:** 2027-08-30
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2025-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07236203

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07236203, "Predictive Factors for the Efficacy of CD19 CAR-T Therapy in Relapsed/Refractory Large B-Cell Lymphoma: A Clinical Study". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07236203. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*